心通醫療-B(02160.HK)香港公開發售獲超769倍認購 上限定價12.2港元/股
格隆匯 2 月 3日丨心通醫療-B(02160.HK)發佈公吿，公司全球發售2.0562億股股份，其中香港發售股份1.0281億股，國際發售股份1.0281億股，另有15%超額配股權；發售價釐定為每股股份12.20港元，每手買賣單位1000股；摩根大通、花旗及中金公司為聯席保薦人，預期股份將於2021年2月4日於聯交所主板掛牌上市。
國際發售項下初步提呈發售的發售股份已獲超額認購，約為國際發售項下初步可供認購股份總數的54倍以上。香港公開發售提呈發售的發售股份已獲極大幅超額認購。合共接獲567,475份有效申請，認購合共158.24億股香港發售股份，相當於香港公開發售項下初步可供認購香港發售股份總數的約769倍以上。
按發售價每股股份12.20港元計算及根據與基石投資者訂立的基石投資協議，基石投資者已認購7943.3萬股發售股份，相當於緊隨全球發售完成後公司已發行股本約3.4%，及相當於全球發售項下發售股份數目約38.6%(假設超額配售權未獲行使)。
按發售價每股股份12.20港元計算，公司將收取的全球發售所得款項淨額估計約為23.56億港元。其中，該等所得款項淨額30.0%將被分配予集團的核心產品(即VitaFlowTM II)；3.4%將被分配予集團首款商業化TAVI產品(即VitaFlowTM)；27.0%將被分配予集團目前產品管線的其他產品；15.0%將獲分配用於為通過與全球賦能者合作擴展集團的產品組合提供資金；14.6%將用於擴大集團的產能並提高集團生產VitaFlowTM及VitaFlowTM II的能力；及10.0%將用作集團的營運資金及一般公司用途。倘超額配售權獲悉數行使，按發售價每股股份12.20港元計算，公司將就配發及發行的3084.3萬股額外股份收取所得款項淨額約3.612億港元。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app！
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.
